| Crizotinib | Chemotherapy | Source |
---|---|---|---|
MOLECULAR TESTING | |||
 ROS1+ prevalence | 1.64% | Rossi et al. [12] | |
 Testing strategy proportion (IHC -> FISH) | 100.0% | Assumption | |
 IHC specificity rate | 83.0% | Viola et al. [13] | |
 IHC sensitivity rate | 100.0% | Viola et al. [13] | |
 FISH specificity rate | 100.0% | Viola et al. [13] | |
 FISH sensitivity rate | 100.0% | Viola et al. [13] | |
EFFICACY PARAMETERS | |||
 Treatment Efficacy | |||
 First line PFS (Months) | 16.2 | 7.79 | Combined analysis (See text) |
 Median second-line PFS (Months) (Crizotinib arm – from combined analysis; Chemo arm – Checkpoint inhibitor/docetaxel) | 7.79 | 3.26 | Combined analysis (See text) |
 HR for pemetrexed maintenance | 0.62 | Paz-Ares et al. [23] | |
 Median PFS for second- or third-line checkpoint inhibitor/docetaxel (Months) | 3.26 | ||
 Median OS during palliation (Months) | 4.60 | Shepherd et al. [28] | |
Percent receiving Treatments | |||
 % receiving pemetrexed maintenance | 50.0% | Assumption | |
 % receiving docetaxel versus checkpoint inhibitor | 50.0% | Assumption | |
 % receiving treatment during palliation | 50.0% | 0% | Assumption |
Transition splits | |||
 PFS to second-line treatment | 70.0% | Assumption | |
 Second-line treatment to third-line treatment | 60.0% | Assumption | |
 Third-line treatment to palliation | 60.0% | Assumption | |
 Proportion not treated after PFS to palliation (vs death) | 33.3% | Assumption | |
 Proportion not treated after second-line treatment to palliation (vs death) | 50.0% | Assumption | |
COSTS | |||
 Testing Costs | |||
  IHC test cost | $42.36 | NA | Djalalov et al. [9] |
  FISH test cost | $410.93 | NA | Djalalov et al. [9] |
 Drug Costs | |||
  Crizotinib (per tablet) | $130.00 | NA | ODB Formulary [29] |
  Pemetrexed (per mg) | $0.21 | CCO [30] | |
  Docetaxel (per mg) | $0.27 | CCO [30] | |
  Pembrolizumab (per mg) | $44.00 | CCO [30] | |
  Nivolumab (per mg) | $19.56 | CCO [30] | |
 Other Costs | |||
  Treatment administration + monitoring costs (monthly) | $1176.83 | $1566.81 | CCO, Schedule of benefits [31] |
  Total AE cost (first-line treatment) | $67.06 | $318.68 | OCC-CAT [32] |
  Palliation cost (monthly) | $3124.07 | De Oliviera et al. [33] | |
UTILITY INPUTS | |||
  Treatment-specific HRQoL (by line) | |||
  PFS – first-line treatment | 0.806 | 0.776 | Solomon et al. [5] |
  Second- or third-line treatment | 0.660 | Shaw et al. [6] | |
  Palliative Care | 0.473 | Nafees et al. [34] | |
Disutility Estimates | |||
 Adverse event disutility estimate | −0.0194 | − 0.0546 | Calculation |